Skip to content

Bio-Techne TECH Operating Segments — Operating Income

Discontinued — last reported Q2 '18

Similar metrics at other companies

Align Technology logo
ALGNOperating Segments — Operating Income
$153.57M+36.7%
Charles River Laboratories logo
CRLOperating Segments — Operating Income
$107.91M+5.1%
Bruker logo
BRKROperating Segments — Operating Income
$106.6M+4.9%
Baxter International logo
BAXOperating Segments — Operating Income
$834M+7.5%
Fair Isaac logo
FICOOperating Segments — Operating Income
$68.83M+8.3%
Cognizant logo
CTSHOperating Segments — Operating Income
$1.16B+4.3%

Other financials

Income statement

See full
Revenue$311.4M-1.5%
Gross profit$208.3M-2.9%
Operating income$75.5M+95.0%
Net income$51.0M+126%
EPS (diluted)$0.32+129%

Balance sheet

See full
Cash & equivalents$209.8M+49.2%
Total debt$290.3M-31.4%
Total equity$2.1B+3.3%
Total assets$2.6B-3.5%

Cash flow

See full
Operating cash flow$86.7M+111%
CapEx$9.1M-10.2%
Free cash flow$77.6M+150%

Valuation

See full
Market cap$9.07B-11.8%
Enterprise value$9.15B-13.6%
P/E60.6×+13.6×
P/S7.5×-1.0×

Profitability

See full
Gross margin65%-0.8pp
Operating margin14.2%-7.9pp
Net margin10.9%-6.7pp
FCF margin22.3%+4.0pp

Returns & leverage

See full
Return on equity6.5%-3.9pp
Debt / equity0.1×-0.1×
Current ratio4.5×+0.8×

Where this comes from

Reported directly by Bio-Techne in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Bio-Techne’s 10-Q, filed February 8, 2018, on SEC EDGAR. View the filing →

Questions, answered.

What does operating segments — operating income mean?
The profit or loss earned by a specific business segment from its core operations.
How do you interpret operating segments — operating income?
An increase indicates improved operational efficiency or higher margins within that segment, while a decrease may signal rising costs or competitive pressure.
How does operating segments — operating income compare across companies?
Peers in the life sciences sector typically report segment operating income to highlight the profitability of their core research and diagnostic divisions.